A post hoc analysis of the SCORED trial suggested the clinical benefit of sotagliflozin on heart failure and MACE-related outcomes in as early as 3 months in a high-risk population.
Christian Ruff, MD, MPH discusses results from the phase 2 AZALEA-TIMI 71 trial, the need for new antithrombotic therapies, and the net clinical benefit outcome of abelacimab for AF.
In an interview at AHA 2023, Deepak Bhatt, MD, MPH, discusses recent advancements in cardiovascular risk management, with a focus on the evolving recognition of inflammation, Lp(a), and obesity as modifiable risk factors.
In this episode, hosts sit down between sessions at AHA 2023 to discuss the landmark SELECT trial, their interpretation of the data, and its implications for care moving forward. Later in the episode, hosts break down the DAPA-MI trial.
Participants with heart failure measured lower on physical and mental component scores than patients with lung, colon, breast, or prostate cancer, highlighting their worser health-related quality of life.
Presented at AHA 2023, the topline analysis of the phase 2 AZALEA-TIMI 71 trial showed abelacimab significantly reduced bleeding in people with Afib at risk of stroke, compared with rivaroxaban.
Brendon Neuen, MBBS, PhD, discusses the results of a study he presented at AHA 2023 estimating the lifetime benefit of combination therapy in patients with type 2 diabetes and albuminuria.
In this episode, hosts take a deep dive into the study’s results, including secondary endpoints, and what it means for the care of patients with overweight or obesity and preexisting cardiovascular disease in real-world settings.
Full data from the SELECT trial offer insight into the 20% relative risk reduction associated with use of semaglutide 2.4 mg in patients with overweight or obesity and preexisting cardiovascular disease at AHA 2023.